Variable | Time from the Last Gemfibrozil Dose | |||
---|---|---|---|---|

1 h | 24 h | 48 h | 96 h | |

Gemfibrozil | ||||

C_{0} (μg/ml) | 17.7 ± 8.5 | 0.13 ± 0.06 | 0.009 ± 0.007 | <0.0025 |

C_{max} (μg/ml) | 26.2 ± 8.7 | |||

t_{max} (min) | 40 (0–80) | |||

t_{1/2} (h) | 1.8 ± 0.3 | 3.8 ± 0.9 | 7.3 ± 2.4 | |

AUC_{0–9 h} (μg × h/ml) | 60.8 ± 19.2 | 0.52 ± 0.28 | 0.048 ± 0.029 | <0.023 |

Gemfibrozil 1-O-β-glucuronide | ||||

C_{0} (μg/ml) | 13.8 ± 5.3 | 0.18 ± 0.11 | 0.008 ± 0.005 | <0.0025 |

C_{max} (μg/ml) | 28.8 ± 7.0 | |||

t_{max} (min) | 80 (40–120) | |||

t_{1/2} (h) | 2.0 ± 0.3 | 3.7 ± 0.6 | 7.8 ± 2.6 | |

AUC_{0–9 h} (μg × h/ml) | 105.6 ± 25.4 | 0.74 ± 0.43 | 0.043 ± 0.023 | <0.023 |

AUC

_{0–9 h}, area under the plasma concentration-time curve from time 0 to 9 h after repaglinide administration, i.e., beginning 1, 24, 48, or 96 h after the last gemfibrozil dose.